The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a huge mover today! About 419,118 shares traded hands. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 55.43% since March 9, 2016 and is uptrending. It has outperformed by 48.02% the S&P500.
The move comes after 5 months negative chart setup for the $291.50 million company. It was reported on Oct, 12 by Barchart.com. We have $3.63 PT which if reached, will make NASDAQ:BCRX worth $34.98M less.
Analysts await BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report earnings on November, 3. They expect $-0.23 earnings per share, down 15.00% or $0.03 from last year’s $-0.2 per share. After $-0.22 actual earnings per share reported by BioCryst Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 4.55% negative EPS growth.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Coverage
Out of 8 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 4 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 50% are positive. BioCryst Pharmaceuticals has been the topic of 18 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating given on Friday, October 9 by Bank of America. As per Tuesday, February 9, the company rating was downgraded by JP Morgan. The firm earned “Buy” rating on Tuesday, February 9 by Jefferies. As per Friday, August 12, the company rating was upgraded by PiperJaffray. On Tuesday, February 9 the stock rating was downgraded by Needham to “Hold”. JMP Securities downgraded the shares of BCRX in a report on Thursday, August 4 to “Market Perform” rating. The firm has “Buy” rating given on Wednesday, January 6 by Jefferies. The firm has “Buy” rating by Rodman & Renshaw given on Tuesday, February 9. As per Friday, August 5, the company rating was maintained by Jefferies. The company was maintained on Tuesday, February 9 by FBR Capital.
According to Zacks Investment Research, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.”
Insitutional Activity: The institutional sentiment decreased to 0.79 in Q2 2016. Its down 0.31, from 1.1 in 2016Q1. The ratio is negative, as 17 funds sold all BioCryst Pharmaceuticals, Inc. shares owned while 31 reduced positions. 10 funds bought stakes while 28 increased positions. They now own 45.48 million shares or 10.25% less from 50.68 million shares in 2016Q1.
Creative Planning has 0% invested in the company for 16,400 shares. Moreover, Baker Bros Advsrs Lp has 0.45% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 15.01M shares. Moreover, Glenmede Na has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 200 shares. Planning accumulated 41,000 shares or 0.01% of the stock. Kcg owns 10,511 shares or 0% of their US portfolio. Blackrock Advisors has invested 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Natl Bank Of Montreal Can has 1,000 shares for 0% of their US portfolio. Alliancebernstein Lp reported 136,020 shares or 0% of all its holdings. California Pub Employees Retirement System has invested 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Tiaa Cref Mgmt last reported 0% of its portfolio in the stock. Wells Fargo And Mn holds 0% or 21,830 shares in its portfolio. Tang Capital Mngmt Limited Company holds 0.54% or 430,000 shares in its portfolio. Blackrock Institutional Com Na has invested 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Department Mb Financial Bank N A, a Illinois-based fund reported 5,225 shares. Citigroup owns 21,438 shares or 0% of their US portfolio.
Insider Transactions: Since August 9, 2016, the stock had 0 buys, and 5 selling transactions for $20.50 million net activity. Babu Yarlagadda S also sold $121,800 worth of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Thursday, August 25. Another trade for 14,577 shares valued at $64,576 was made by STAAB THOMAS R II on Tuesday, August 9. Barnes Alane P sold $35,684 worth of stock or 8,357 shares. BAKER BROS. ADVISORS LP also sold $20.25 million worth of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Friday, August 12.
More news for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) were recently published by: Prnewswire.com, which released: “Biotech Stocks on Investors’ Radar — Alexion Pharma, PDL BioPharma, BioCryst …” on October 12, 2016. Seekingalpha.com‘s article titled: “BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 2016 Results …” and published on August 05, 2016 is yet another important article.
BCRX Company Profile
BioCryst Pharmaceuticals, Inc. (BioCryst), incorporated on November 15, 1991, is a biotechnology company. The Firm designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Firm focuses on the treatment of rare diseases. The Firm uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company’s drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.